Posted on November 16, 2026 by Sally-Anne Turner
Why are GLP-1’s like weight loss jabs suddenly everywhere?
We mentioned before that it seems that GLP-1 medications are breaking out of their boxes and being explored in areas from cardiovascular disease to mental health.
Of course, to back this up, there is more research and even new GLP-1 and GLP-1/GIP agonists being created and trialled around the world. And our team at the Bodyline Clinic are here to give you the newest breakthroughs, insights and research summaries in the world of weight-loss medications.
So, welcome to Pills, Pens and Progress 16!
We’ve spoken about Retatrutide in the past. And it seems that beyond the TRIUMPH 2 trial, which we mentioned in Pills Pens and Progress 12, the phase 3 TRANSCEND-T2D-2 trial has explored the impact that the drug had on 1,298 adults who had type 2 diabetes.
As we know, Retatrutide targets three hormones and Eli Lilly (the creator of this drug and Mounjaro) has conducted research into this drug and injections with Ozempic 2mg over 80 weeks.
Participants received Retatrutide 9mg and lost an average of 19.5% of their body weight, and those who were taking 12 mg lost 20.9%. This was compared to 9.4% of participants who were receiving Ozempic.
However (there’s always a however with us at the Bodyline Clinic!), the trial tested Ozempic 2 mg in adults with obesity. It does not establish if Retatrutide is better for those without diabetes who are seeking to lose weight alone.
Eli Lilly also reported that those in the trial noted improvements in cardiovascular risk factors, in particular, blood pressure and cholesterol.
It’s a GLP-1-like drug and as such, Retatrutide had digestive side effects. These led to more participants stopping this drug more commonly than Ozempic.
Can you get Retatrutide UK? Not legally! It is not authorised for use, and the MHRA warns against buying products that have not passed through legitimate clinical trials.
See the original news piece here— https://abcnews.com/GMA/Wellness/new-weightloss-drug-retatrutide-double-weight-loss-ozempic/story?id=137614872&
Theres a new name that is predicted to soon by in the weight loss market.
Called Eppe, it was developed by Hanmi Pharmaceutical and it has become South Korea’s first domestically developed GLP-1 obesity medicine, after it was approved on 7th of October 2026. Indeed, on the 29th of October, it will hit selected Korean clinics.
What’s in it? As far as weight loss jabs go, it acts on GLP-1 receptors and has the active ingredients efpeglenatide, which slows gastric emptying. As with other GLP-1’s, the approval in Korea notes it as covering chronic weight management without diabetes along with dietary and exercise changes.
Hanmi’s interim phase 3 results involved 448 Korean adults.
After 40 weeks, participants receiving efpeglenatide lost:
These are company-reported findings, and individual results varied.
This trial compared these results with placebo, so it has to be noted that it may not be more effective or better tolerated than Mounjaro or Wegovy.
At the time of writing, this is still in the clinical stage and Eppe is not available for purchase legally in the UK.
Learn more here— https://m.ajupress.com/amp/20261023104607573
We have spoken at length about mental health and GLP-1’s.
However, this is an area that is expanding rapidly, relating to addiction and now, even more complicated mental health issues and brain disorders, such as schizophrenia and Parkinsons disease.
A Nature report highlights growing investment in compounds being developed specifically for these potential uses. However, as always, these are experimental and it needs to be stated that this does NOT mean that GLP-1s should be used to treat mental health issues or brain conditions.
So, one medication that is being tried is brenipatide. This is an experimental medication from Eli Lilly that targets both GLP-1 and GIP receptors. This remains active in the body longer than currently approved GLP-1 treatments. This is being investigated for its use in alcohol, tobacco and opioid use, alongside depression, bipolar and even schizophrenia. It has not been researched relating to paranoid schizophrenia, anxiety or PTSD.
At the time of writing, it has not been determined if this new GLP-1 impacts on these conditions.
Relating to Parkinsons, researchers are testing KP405. This is a compound that is designed to enter the brain and is a GLP-1/GIP agonist. At the time of writing, there has been early biomarker findings that point to possible brain penetration but do not currently highlight a clinical benefit.
See the original research here— Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial | American Journal of Psychiatry
We’ve said it before and we will say it again. The area of GLP-1 research is always moving. That means that it can be hard for people searching for GLP-1 treatments to decide which option may be right for them.
As always, our team at the Bodyline Clinic is here not only to talk to you about the right GLP-1 treatment for you, or the best weight loss pills but to also offer you support during your weight loss. We don’t offer a quick sign-off with our medications and we pride ourselves on offering a comprehensive, clinically supported approach to weight loss.
So, if you need more than a 5-minute consultation or have some queries about how we may be able to help you, contact our team today at the Bodyline Clinic.
BMI calculator
Enter your height and weight to work out your Body Mass Index in seconds.
Your BMI
Find out where you sit and what your options are
Your BMI
Our CQC-regulated clinical team will confirm your eligibility at consultation, in clinic or by video.
CQC regulated 4.8 on Trustpilot
If you'd like advice on your health and wellbeing, our team can talk you through the services we offer.
Explore our servicesWe'd recommend speaking to your GP, who can check everything is OK and offer the right support.
BMI ranges work differently for under 18s. Please speak to your GP for advice.
Please check your height and weight.
Contact us today
Find out more about how we can treat and support you to improve your health and wellbeing.
No-obligation advice from our CQC-regulated team, in clinic or by video.